Drugs / Adebrelizumab
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07266480 | Sep 2025 → Sep 2027 expected | esophageal squamous cell carcinoma | Hebei Medical University Fourth Hospital | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Adebrelizumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07266480 ↗ |
| Route | Intravenous | “Adebrelizumab: 1200mg, iv, d1, q3w, 17 cycles” NCT07266480 ↗ |